Method Development Insights

Getting Method Development Right: What Bioanalytical Sponsors Must Bring to the Table

Method development is the first real moment of truth in a bioanalytical project. It sets the trajectory for everything that follows, from validation to sample analysis to final reporting.

And yet, one of the most common challenges we see is not technical. It is alignment.

Strong method development does not start in the lab. It starts with what the sponsor brings into the conversation.

Why This Matters 

A well-developed method is not just about sensitivity or selectivity. It is about fitness for purpose.

If the foundation is unclear, teams end up iterating, reworking, and losing time. In early development programs, that time matters.

The difference between a smooth program and a reactive one often comes down to the quality of inputs at the start.

What Sponsors Should Provide Upfront 

1. Clear Study Objectives

What decisions will this data support? This sounds simple, but it drives everything:

• required sensitivity (LLOQ)
• dynamic range
• turnaround expectations
• regulatory expectations

Without this, method development becomes guesswork.

2. Molecule Understanding

Basic characterization is critical:

• structure and class (small molecule, peptide, ADC, etc.)
• solubility
• known metabolites or expected biotransformations
• stability profile (if known)

Any previous observations helps the lab anticipate challenges early.

3. Matrix and Species Strategy

Where will this method be applied?

• preclinical species vs. clinical
• plasma, serum, tissue, or microsamples
• special populations or conditions

Matrix drives complexity. Tissue and microsampling require very different approaches than standard plasma work.

4. Expected Concentration Ranges

Even rough estimates are valuable:

• C_max expectations
• anticipated PK profile
• dose levels

This informs assay range and avoids rework when real samples arrive.

5. Reference Materials and Standards

Availability and quality matter:

• certificate of analysis
  • purity
  • storage conditions
• API standards
• internal standards
• metabolite standards (if applicable)

Delays here can stall development entirely.

6. Regulatory Context

Is this:

• exploratory
• GLP toxicology
• clinical (GCP-aligned)

The level of rigor and documentation changes based on intended use.

7. Timeline and Priorities

Be explicit:

• key milestones
• critical path studies
• flexibility vs. fixed deadlines

This helps labs allocate resources appropriately and avoid surprises.

Where Things Break Down 

Most issues we see are not capability gaps. They are communication gaps.

• assumptions about expected sample concentrations
• late changes in matrix or species
• misalignment on regulatory expectations

These lead to avoidable delays and rework.

Best Practice: Treat Method Development as a Partnership 

The most successful programs share a common approach:

• early, direct communication with scientific teams
• transparent discussion of risks and unknowns
• willingness to align on “fit-for-purpose” vs. “perfect”

Method development is not a transactional step. It is a strategic one.

Final Thought 

If you want speed, quality, and reliability downstream, invest the time upfront. The best bioanalytical methods are not just developed. They are built on clarity.

Looking for more information on method development?

Download the “Getting Method Development Right: What Bioanalytical Sponsors Must Bring to the Table” Infographic
An easy-to-use reference that highlights seven key elements

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.

Method Development Expectations: Where Programs Quietly Go Off Track

Method development rarely fails because of technical limitations. It fails because expectations were never clearly defined.

And the issue often starts early, even if it is not recognized until much later.

At Alturas, we consistently see that misalignment at this stage does not stop progress. It redirects it.

Why This Matters

When expectations are unclear, teams keep moving. But they move in the wrong direction.

Time is spent optimizing performance that may not be required. Complexity is introduced without purpose. And what should be structured iteration becomes reactive troubleshooting.

We recently saw a program where an aggressive LLOQ target was set without a clear link to study decisions. The result was weeks of added development time with no impact on the outcome of the study.

In early-stage programs, that time matters.

What Needs to Be Defined Early

1. Fit-for-Purpose Performance: The key decision at this stage is simple: What does the method actually need to do? Define required sensitivity, acceptable variability, and the decisions the data must support. Without this, teams default to building toward an undefined 'best case.'
2. The Role of Iteration: Method development is inherently iterative across extraction, chromatography, and detection. Iteration is not inefficiency; it is the process.
3. Trade-Offs Must Be Explicit: Every method balances sensitivity, robustness, and throughput. In one program, aligning early that robustness mattered more than absolute sensitivity reduced complexity and accelerated delivery.
4. Timeline vs. Complexity: Faster timelines always come with trade-offs. The decision is what can be relaxed to move faster.

Where Things Break Down

• validation-level expectations applied too early
• sensitivity targets pushed beyond study needs
• matrix complexity underestimated
• timelines compressed without defined trade-offs

Best Practice: Align Before You Optimize

At Alturas, we approach method development as a decision-making phase, not just execution.

Define success early, align on trade-offs, and accept iteration as part of the process.

Final Thought

If method development feels unpredictable, it is rarely the science. It is the absence of clearly defined expectations.

Clarity does not eliminate iteration. It makes iteration productive.

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.

Method Development: Where You Start Determines Where You End Up

Most method development challenges do not come from complexity. They come from where the process starts.

Too often, method development begins at the instrument instead of at the problem.

Why This Matters

Starting in the wrong place compounds inefficiency. Teams waste time optimizing parameters before confirming method objectives.

Where Method Development Should Start

1. Understand the Molecule: Structure, solubility, stability, and expected metabolites are key to developing the assay efficiently.
2. Define the Matrix: Plasma vs. tissue vs. microsamples introduce different biological challenges that need to be overcome during method development.
3. Confirm Detection Feasibility: Can the analyte be detected with acceptable signal-to-noise and selectivity at the desired LLOQ?
4. Start Simple: Begin with straightforward extraction (e.g., protein precipitation) and add complexity only when required.

Where Things Break Down

• jumping straight to instrumentation and extraction
• not researching the molecule
• reinventing previous methods that worked
• underestimating matrix impact

Best Practice: Build, Don’t Guess

At Alturas, we start with fundamentals, confirm feasibility early, and build complexity only when needed.

Final Thought

Where you start determines how efficient method development becomes. Start with the problem, not the instrument.

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.

Avoiding the Pitfalls of Method Development Before They Cost You Time

Most method development problems are not surprises.

They are predictable.

The issue is not that they occur. It is when they are identified.

Why This Matters

Late-stage issues are expensive to fix.

Repeating experiments to address these issues can cost your program extra time and money.

Common Pitfalls

1. Over-Optimization Too Early — Refining performance before confirming objectives decreases efficiency.
2. Late Identification of Matrix Effects — Co-elution and ion suppression must be evaluated early.
3. Stability Assumptions — Unverified stability can invalidate data and force revalidation.
4. Chasing Unnecessary Sensitivity — Lower LLOQ is not always better; it often adds complexity and results in unnecessary sample dilution.

Where Things Break Down

• matrix effects and stability not assessed
• optimization without clear objectives

Best Practice: Identify Risk Early

At Alturas, we prioritize simplest extraction possible, matrix effects evaluation and matrix stability checks to prevent downstream rework.

Final Thought

The fastest programs are not the ones that fix problems quickly.

They are the ones that prevent them.

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.